Abstract:Growth hormone (GH)‐secreting pituitary adenoma is a severe endocrine disease. Surgery is the currently recommended primary therapy for patients with GH‐secreting tumours. However, non‐surgical therapy (pharmacological therapy and radiation therapy) may be performed as primary therapy or may improve surgical outcomes. To assess the effects of surgical and non‐surgical interventions for primary and salvage treatment of GH‐secreting pituitary adenomas in adults. We searched CENTRAL, MEDLINE, WHO ICTRP, and ClinicalTrials.gov. The date of the last search of all databases was 1 August 2022. We did not apply any language restrictions. Randomised controlled trials (RCTs) and quasi‐RCTs of more than 12 weeks' duration, reporting on surgical, pharmacological, radiation, and combination interventions for GH‐secreting pituitary adenomas in any healthcare setting. Two review authors independently screened titles and abstracts for relevance, screened for inclusion, completed data extraction, and performed a risk of bias assessment. We assessed studies for overall certainty of the evidence using GRADE. We estimated treatment effects using random‐effects meta‐analysis. We expressed results as risk ratios (RR) for dichotomous outcomes together with 95% confidence intervals (CI) or mean differences (MD) for continuous outcomes, or in descriptive format when meta‐analysis was not possible. We included eight RCTs that evaluated 445 adults with GH‐secreting pituitary adenomas. Four studies reported that they included participants with macroadenomas, one study included a small number of participants with microadenomas. The remaining studies did not specify tumour subtypes. Studies evaluated surgical therapy alone, pharmacological therapy alone, or combination surgical and pharmacological therapy. Methodological quality varied, with many studies providing insufficient information to compare treatment strategies or accurately judge the risk of bias. We identified two main comparisons, surgery alone versus pharmacological therapy alone, and surgery alone versus pharmacological therapy and surgery combined. Surgical therapy alone versus pharmacological therapy alone Three studies with a total of 164 randomised participants investigated this comparison. Only one study narratively described hyperglycaemia as a disease‐related complication. All three studies reported adverse events, yet only one study reported numbers separately for the intervention arms; none of the 11 participants were observed to develop gallbladder stones or sludge on ultrasonography following surgery, while five of 11 participants experienced any biliary problems following pharmacological therapy (RR 0.09, 95% CI 0.01 to 1.47; 1 study, 22 participants; very low‐certainty evidence). Health‐related quality of life was reported to improve similarly in both intervention arms during follow‐up. Surgery alone compared to pharmacological therapy alone may slightly increase the biochemical remission rate from 12 weeks to one year after intervention, but the evidence is very uncertain; 36/78 participants in the surgery‐alone group versus 15/66 in the pharmacological therapy group showed biochemical remission. The need for additional surgery or non‐surgical therapy for recurrent or persistent disease was described for single study arms only. Surgical therapy alone versus preoperative pharmacological therapy and surgery Five studies with a total of 281 randomised participants provided data for this comparison. Preoperative pharmacological therapy and surgery may have little to no effect on the disease‐related complication of a difficult intubation (requiring postponement of surgery) compared to surgery alone, but the evidence is very uncertain (RR 2.00, 95% CI 0.19 to 21.34; 1 study, 98 participants; very low‐certainty evidence). Surgery alone may have little to no effect on (transient and persistent) adverse events when compared to preoperative pharmacological therapy and surgery, but again, the evidence is very uncertain (RR 1.23, 95% CI 0.75 to 2.03; 5 studies, 267 participants; very low‐certainty evidence). Concerning biochemical remission, surgery alone compared to preoperative pharmacological therapy and surgery may not increase remission rates up until 16 weeks after surgery; 23 of 134 participants in the surgery‐alone group versus 51 of 133 in the preoperative pharmacological therapy and surgery group showed biochemical remission. Furthermore, the very low‐certainty evidence did not suggest benefit or detriment of preoperative pharmacological therapy and surgery compared to surgery alone for the outcomes 'requiring additional surgery' (RR 0.48, 95% CI 0.05 to 5.06; 1 study, 61 participants; very low‐certainty evidence) or 'non‐surgical therapy for recurrent or persistent disease' (RR 1.22, 95% CI 0.65 to 2.28; 2 studies, 100 participants; very low‐certainty evidence). None of the included studi -Abstract Truncated-

Significance of the Growth Hormone in Assessment of Surgical Remission and Prognosis in Pituitary GH

Surgical Results and Predictors of Initial and Delayed Remission for Growth Hormone-Secreting Pituitary Adenomas Using the 2010 Consensus Criteria in 162 Patients from a Single Center

Effects of transsphenoidal surgery on anterior pituitary function in growth hormone-secreting pituitary adenomas and analysis of related factors

The Diagnosis and Treatment of Growth Hormone Secreting Pituitary Adenomas: Analysis of 95 Cases

Author Response for "2010 Versus the 2000 Consensus Criteria in Patients with Normalised Insulin‐like Growth Factor 1 after Transsphenoidal Surgery Has High Predictive Values for Long‐term Recurrence‐free Survival in Acromegaly"

Characteristics of Glucose Metabolism in Patients with Pituitary Growth Hormone Secreting Adenomas and the Impact of Trans?sphenoid Surgery

Perioperative hormone level changes and their clinical implications in patients with pituitary adenoma: a retrospective study of 428 cases at a single center

Surgical Outcomes and Predictors of Glucose Metabolism Alterations for Growth Hormone-Secreting Pituitary Adenomas: a Hospital-Based Study of 151 Cases.

The comprehensive impact on human body induced by resolution of growth hormone excess.

Clinical Analysis of Adult Growth Hormone Deficiency on the Postoperative Patients with Pituitary Adenoma

Surgical Treatment of Growth Hormone Pituitary Tumors Complicated with Cardiomyopathy

Association of different pathologic subtypes of growth hormone producing pituitary adenoma and remission in acromegaly patients: a retrospective cohort study

Effect of Presurgical Long-Acting Octreotide Treatment in Acromegaly Patients with Invasive Pituitary Macroadenomas: A Prospective Randomized Study

Comparative Effectiveness of Endoscopic Versus Microscopic Transsphenoidal Surgery for Patients with Growth Hormone Secreting Pituitary Adenoma: an Emulated Trial

Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults

Pre- and Postoperative Health Status of Patients with Nonfunctioning and Secretory Pituitary Adenomas and an Analysis of Related Factors.

Efficacy of transsphenoidal surgery in achieving biochemical cure of growth hormone-secreting pituitary adenomas among patients with cavernous sinus invasion: a systematic review and meta-analysis

Clinical characteristics and prognostic factors of prolactinomas and growth hormone-secreting adenomas in premenopausal women in China

Preoperative Somatostatin Analogs Treatment in Acromegalic Patients with Macroadenomas. A Meta-Analysis

Early Predictors of Remission in Acromegaly Patients after Pure Endoscopic Endonasal Transsphenoidal Surgery

Outcome of Postoperative Hypopituitarism and Hormone Replacement Situation in 215 Patients with Pituitary Adenoma